Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 4/20 | 0.33 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822941 | 0.95 | HTT (0.45) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL822794 | 0.92 | HTT (0.43) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL13598293 | 0.91 | HTT (0.39) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL2696779 | 0.90 | HTT (0.41) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL2695193 | 0.85 | HTT (0.45) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL2695302 | 0.84 | CA1 (0.36) | HTTTDP1SMN1; SMN2BCHEACHE | |
| SCHEMBL13598288 | 0.82 | HTT (0.44) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL2695196 | 0.82 | HTT (0.42) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL822855 | 0.82 | HTT (0.56) | HTTTDP1L3MBTL1SMN1; SMN2BCHE | |
| SCHEMBL822860 | 0.80 | SRD5A2 (0.35) | HTTSMN1; SMN2KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-11-18 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| US-20090326188-A1 | Method for producing polyarylene | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | C9, H1-10, CYP1A1 | HTT 1768/4885TDP1 4003/4885L3MBTL1 602/4885 |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | HTT 1789/4885TDP1 3931/4885L3MBTL1 2833/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | HTT 2006/4885TDP1 4012/4885L3MBTL1 2253/4885 |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | TYR, PAH, AHR | HTT 1087/4885TDP1 4605/4885L3MBTL1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.